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Objective. The aim of the study was an evaluation of possible relationships between polymorphisms of serotoninergic system
genes and the risk of depression in postmenopausal women. Methods. We studied 332 women admitted to our department
because of climacteric symptoms. The study group included 113 women with a diagnosis of depressive disorder according to the
Hamiltonratingscalefordepression;thecontrolsconsistedof219womenwithoutdepression.Serum17β-estradiolconcentrations
were evaluated using radioimmunoassay, while polymorphisms in serotoninergic system genes: serotonin receptors 2A (HTR2A),
1B (HTR1B), and 2C (HTR2C); tryptophan hydroxylase 1 (TPH1)a n d2( TPH2), and monoamine oxidase A (MAO-A)w e r e
evaluated using polymerase chain reaction-restriction. Results. We found that the 1460T allele of MAO-A c.1460C>T (SNP
1137070) appeared with a signiﬁcantly higher frequency in depressed female patients than in the control group (P = 0.011)
and the combined c.1460CT + TT genotypes were associated with a higher risk of depression (P = 0.0198). Patients with the
1460TT genotype had a signiﬁcantly higher 17β-estradiol concentration than patients with the 1460CT genotype (P = 0.0065)
and 1460CC genotype (P = 0.0018). Conclusions. We concluded that depression in postmenopausal women is closely related to
the genetic contribution of MAO-A.
1.Introduction
The central serotoninergic system has been implicated in the
pathophysiology of a number of neuropsychiatric disorders
such as mood disorders, substance abuse, or alcoholism [1,
2]. Well-studied components of this system are the serotonin
(5-HT) receptors 2A (5-HT2A), 1B (5-HT1B), and 2C (5-
HT2C), and the key regulators of 5-HT metabolism: tryp-
tophan hydroxylase 1 and 2 (TPH1 and TPH2) and mo-
noamine oxidase A (MAO-A)( Figure 1). The receptors 5-
HT2A, 5-HT2C, and 5-HT1B are members of a family of
receptors linked to guanine-nucleotide-binding proteins (G-
protein-coupled receptor; GPCR) expressed on the cell body
and dendrites of serotoninergic neurons in the brain [3].
The receptors 5-HT2A and 5-HT2C are the main excitatory
receptor subtypes among the GPCRs for 5-HT, whereas
the 5-HT1B receptor is thought to act as a nerve terminal
autoreceptor, inhibiting the release of 5-HT. After acting at
its receptor, 5-HT is metabolized by MAO-A (Figure 1), and
therefore MAO activity may play a critical role in the regula-
tion of the serotoninergic system and in the pathogenesis of
depressive disorders [4].
The gene encoding 5-HT2A (HTR2A) is considered to
be a candidate gene for depression. Genetic association has
been reported between the c.102C>T polymorphism in the
HTR2A gene and depression, as well as suicidal behavior
in patients with mood disorders and schizophrenia [5–7],
althoughseveralstudieshavefailedtoreplicatetheseﬁndings
[8]. It is likely that other serotoninergic genes are involved in
gene-environmentinteractionsrelatedtodepression.Among
them, the gene encoding the 5-HT1B receptor (HTR1B)h a s
been correlated to attempted suicide in patients with major
depression, because altered postmortem 5-HT1B receptor
binding was found to be associated with suicide in some of2 The Scientiﬁc World Journal
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Figure 1: Contribution of tryptophan hydroxylase and MAO in serotonin metabolism. Tryptophan hydroxylase catalyzes the monooxy-
genation of tryptophan to 5-hydroxytryptophan, which is subsequently decarboxylated to form serotonin (5-hydroxytryptamine; 5-HT).
Monoamine oxidase (MAO) catalyzes the oxidative deamination of 5-HT to the corresponding aldehyde. This is followed by oxidation by
aldehyde dehydrogenase to 5-HIAA, the indole acetic acid derivative.
the studies [9]. A common c.861G>Cp o l y m o r p h i s mo ft h e
HTR1B gene was identiﬁed in the coding region of the gene,
and major depression appears to be associated with this locus
[10].Astrongassociationbetweensuicideandreceptorgenes
of the serotoninergic system has presented evidence for yet
another 5-HT receptor gene located on human chromosome
Xq24, the 5-HT2C receptor gene (HTR2C)[ 11]. This recep-
tor mediates the release of dopamine (DA) in the brain and
can cause anxiety, depression, and compulsive behaviors in
human subjects due to the mechanism of rapid downreg-
ulation by serotonin. The structural variant c.68G>C of the
HTR2C gene that gives rise to a cysteine-to-serine substitu-
tion in the N terminal extracellular domain of the receptor
protein (Cys23Ser) has recently been found to be signiﬁ-
cantly associated with female suicide victims [12].
Tryptophan hydroxylase (TPH) is the rate-limiting en-
zyme in the biosynthesis of 5-HT and thus has a major func-
tion in regulating the serotoninergic system [13]. Studies of
the human brain have revealed two isoforms of the gene cod-
ing for tryptophan hydroxylase 1 and 2, termed TPH1 and
TPH2.Oneofthem,theTPH2gene,isofinterestbecausethis
tryptophan hydroxylase 2 isoform regulates the biosynthetic
pathway of 5-HT in the serotoninergic neurons of raphe nu-
clei and has been implicated in the pathogenesis of major
depressive disorder and the mechanism of antidepressant ac-
tion [14].
Investigations of the functional eﬀects of genetic varia-
tions in the TPH2 gene have demonstrated that a haplotype
of 3 SNPs within the gene promoter (−703G>T, −473T>A,
and 90A>G) inﬂuenced transcription in human cell lines.
Similarly, the TPH2 c.1077G>A polymorphism within the
coding region (Pro312Pro; SNP 7305115) increased expres-
sion levels of the gene in the human pons, containing the
dorsalandmedianraphenuclei[15].ThisSNPhaspreviously
demonstrated an association with major depression and sui-
cide [16].
Monoamine oxidase (MAO) is an important enzyme as-
sociated with the metabolism of biogenic amines and neu-
rotransmitters, including norepinephrine (NE), DA, and 5-
HT. Two forms of the enzyme, MAOA and MAOB, are found
in the human brain [17]. Of the two, MAOA exhibits a
higher aﬃnity for 5-HT and NE, whereasDA is preferentially
metabolized by both forms of the enzyme. The MAOA gene
(MAO-A) has been mapped to the short arm of the X chro-
mosome; thus, functional polymorphisms of this locus are
expected to manifest in a sex-speciﬁc fashion. The human
MAO-A contains a variable-number tandem repeat (VNTR)
polymorphism in its promoter region that may alter the
transcriptional eﬃciency of MAOA expression [18]. Most
of the other known MAO-A polymorphisms either aﬀect
intronic sequences or introduce a silent change in the open-
reading frame (i.e., the EcoRV polymorphism and Fnu4HI
polymorphism, SNPs: 1137070 and 6323, resp.). These vari-
ants are unlikely to aﬀect MAO function, although they may
be in disequilibrium with other, as yet unidentiﬁed, func-
tionalvariants.TheprimaryroleofMAOAinregulatingmo-
noamine turnover, and hence ultimately inﬂuencing levels of
NE, DA, and 5-HT, indicates that its gene is a highly plau-
sible candidate for aﬀecting individual diﬀerences in the
manifestation of psychological traits and psychiatric dis-
orders [19, 20]. For example, several studies indicate that
the MAO-A gene may be involved in the pathogenesis of
depression and major depressive disorder [21, 22].
However, genetic factors can modulate the risk for de-
pression by inﬂuencing monoaminergic activity in a sexually
dimorphic manner. Because the MAO-A gene is X-linked,
males are hemizygous at this locus, whereas females are ho-
mozygous or heterozygous. Moreover, the MAO-A EcoRVThe Scientiﬁc World Journal 3
polymorphism was found to be associated with depression
in males but not in females [23, 24]. A sexually dimorphic
pattern of genetic susceptibility to obsessive-compulsive dis-
order (OCD) may also be present [25–27]. Statistically sig-
nificantassociationswereobservedbetweentheallelesforthe
MAO-A EcoRV polymorphism and levels of MAO activity in
human male ﬁbroblast lines [28]. The functional analyses of
this genetic variation have revealed the existence of the high-
activity T allele and the low-activity C allele of the MAO-A
EcoRV polymorphism.
Individuals with a high-activity MAO-A genotype would
be expected to have greater serotonin turnover (Figure 1).
High plasma MAO activity, however, has been found to be
signiﬁcantly correlated with testosterone levels in men and
with 17β-estradiol levels in women, with high testosterone
or 17β-estradiol levels leading to low plasma MAO activity
[29]. Women are more likely than men to develop aﬀective
disorders, including depression, and this risk increases after
menopause, when estrogen production in the ovaries ends
[30–33].Wehypothesizedthatthehigh-activityMAO-Agen-
otypewouldbeassociatedwithdepressioninpostmenopaus-
al women. To test this hypothesis, we evaluated serum 17β-
estradiol concentrations and genotyped the MAO-A EcoRV
polymorphisminagroupofhealthy(n = 219)anddepressed
(n = 113) postmenopausal women. We also used a case-
control study design in the same individuals to investigate
a possible association with a susceptibility to depression of
the SNPs of ﬁve other serotoninergic system genes: 5HTR2A
(SNP 6313), 5HTR1B (SNP 6296), HTR2C (SNP6318),
TPH1 (SNP 1800532), and TPH2 (SNP 7305115).
2. Patientsand Methods
2.1. Patients. We studied three hundred and thirty-two post-
menopausal women, aged 42–67, who were admitted to the
Department of Gynecological Endocrinology, Poznan Uni-
versity of Medical Sciences, because of climacteric com-
plaints. All postmenopausal women had their last menstrual
ﬂow more than 1 year before the study.
All patients were assessed with the Hamilton rating scale
for depression (HRSD) and divided into two groups: diag-
nosed of depressive disorder (113 women) and without de-
pression (219 women served as the control group). Accord-
ing to HRSD, mild depression was deﬁned as a score more
than 7 and less or equal to 17, and moderate depression was
deﬁned as a score more than 17 and less or equal to 25.
The 113 women with depression included 82 women with
mild depression and 31 women with moderate depression.
Noneoftheexaminedwomenwereonhormonereplacement
therapy (HRT) or on psychotropic drugs.
All experiments were carried out after obtaining in-
formed consent from all the participating women. The local
Ethic Review Committee of Poznan University of Medical
Sciences approved the study protocol.
2.2. Blood Samples and Measurements of 17β-Estradiol. A
blood sample was collected from each study participant.
17β-estradiol serum concentrations were quantiﬁed using
radioimmunoassay (RIAs). The intraassay and interassay
coeﬃcients of variation (CV) were 1.2–3.3%, and 2.0–5.6%,
respectively.
2.3. Genotyping by RFLP. Genomic DNA was prepared from
sodium-versenate-(EDTANa2-) treated blood samples. Gen-
otyping for polymorphisms in 5HTR2A c.102C>T( S N P
6313), 5HTR1B c.861G>C (SNP 6296), HTR2C c.68G>C
(SNP6318), MAO-A c.1460C>T (SNP 1137070), TPH1
218C>A (SNP 1800532), and TPH2 c.1077A>G( S N P
7305115) was determined by polymerase chain reaction-re-
striction fragment length polymorphism (PCR-RFLP) assay,
using the appropriate restriction enzymes. The digested PCR
products were resolved on a 2% agarose gel and stained with
ethidium bromide for visualization under UV light.
2.4. Statistical Analysis. The genotype and allele frequencies
of all analyzed polymorphisms were compared between the
group of postmenopausal women with depression and with-
out depression using a case-control study design. Signifi-
cance was evaluated by the Fisher exact test. Odds ratios
(ORs)and95%conﬁdenceintervals(CIs)wereestimatedus-
ingtheGraphPad(Instant,USA)program.Anonline(http://
ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl)p r o g r a m
for deviation from the Hardy-Weinberg equilibrium was ap-
plied. Comparison of the 17β-estradiol serum concentra-
tions between the diﬀerent genotype groups was performed
with the use of the Kruskal-Wallis test.
In all cases, P<0.05 was considered statistically signifi-
cant.
3. Results
In the present study, 113 women with diagnosed mild or
moderate depression (patients) and 219 women without
depression (healthy controls) were genotyped for polymor-
phisms in six serotonergic candidate genes: HTR2A, HTR1B,
HTR2C, TPH1, TPH2,a n dMAO-A. The data for allele fre-
quencies and genotype distribution of these polymorphisms
for the patients and the controls are presented in Table 1.
Distributionofthesepolymorphisms wasconsistentwiththe
Hardy-Weinberg equilibrium in the group with depressive
d i s o r d e r s ,a sw e l la si nt h ec o n t r o lg r o u p .
No signiﬁcant diﬀerences were observed in the frequency
ofeitherthe5HTR2Ac.102C>T, 5HTR1Bc.861G>C,HTR2C
c.68G>C, TPH1 218C>A, or TPH2 c.1077A>Gg e n o t y p e so r
alleles between the patients and the controls (Table 1).
The MAO-A c.1460C>T polymorphism in the patient
group demonstrated a signiﬁcant diﬀerence when compared
to the control group. The frequency of the T allele in the
group of women with depression was higher than that in
the control group (P = 0.011) (Table 1). The frequency of
the homozygous c.1460TT genotype in these groups reached
14% and 8%, respectively (Table 1). Although the frequency
of the heterozygous c.1460CT was higher in women with
depression (50%) than in women without depression (42%),
this was not signiﬁcant (Table 1).
We also undertook the test for association, using c.1460T
as a risk allele (Table 1). The OR and CI were calculated for4 The Scientiﬁc World Journal
Table 1: The genotype distribution between postmenopausal women with (w)a n dw i t h o u t( w/o) depression.
Polymorphism n Genotype and allele distribution absolute number (frequency) Allele P
Value
Genotype
Odds ratio (95%
CI); P Value
CC CT TT CT
5HTR2A c.
102C>T
(SNP 6313)
w depression 50 44 19 144 82 P = 0.735 0.769
(0.485–1.219)a;
P = 0.2634b
Total 113 (0.44) (0.39) (0.17) (0.64) (0.36)
w/o depression 83 107 29 273 165
Total 219 (0.38) (0.49) (0.13) (0.62) (0.38)
GG GC CC GC
5HTR1B c.861G>C
(SNP 6296)
w depression 62 44 7 168 58 P = 0.635 1.094
(0.693–1.728)a;
P = 0.700b
Total 113 (0.55) (0.39) (0.06) (0.74) (0.26)
w/o depression 125 83 11 333 105
Total 219 (0.57) (0.38) (0.05) (0.76) (0.24)
)
GG GC CC GC
0.996
(0.610–1.628)a;
P = 0.989b
5HTR2C c. 68G>C
(SNP 6318)
w depression 78 30 5 186 40 P = 1.000
Total 113 (0.69) (0.27) (0.04) (0.82) (0.18)
w/o depression 151 57 11 359 79
Total 219 (0.69) (0.26) (0.05) (0.82) (0.18)
)
CC CT TT CT
1.772
(1.112–2.825)a;
P = 0.0198∗b
MAO-A
c.1460C>T
(SNP 1137070)
w depression 41 56 16 138 88 P = 0.011∗
Total 113 (0.36) (0.50) (0.14) (0.61) (0.39)
w/o depression 110 91 18 311 127
Total 219 (0.50) (0.42) (0.08) (0.71) (0.29)
)
CC CA AA CA
TPH1 218C>A
(SNP 1800532)
w depression 44 49 20 137 89 P = 0.801 1.014
(0.637–1.615)a;
P = 0.9533b
Total 113 (0.39) (0.43) (0.18) (0.61) (0.39)
w/o depression 86 99 34 271 167
Total 219 (0.39) (0.45) (0.16) (0.62) (0.38)
)
GG GA AA GA
TPH2 c.1077G>A
(SNP 7305115)
w depression 45 51 17 141 85 P = 0.737 0.870
(0.546–1.386)a;
P = 0.5573b
Total 113 (0.40) (0.45) (0.15) (0.62) (0.38)
w/o depression 80 106 33 266 172
Total 219 (0.37) (0.48) (0.15) (0.61) (0.39)
The women’s groups were classiﬁed based on the severity of depression assessed by the Hamilton rating scale for depression: w/o depression (0–7), mild
depression(8–17),andmoderatedepression(18–25).The113womenwithdepressionincluded82womenwithmilddepressionand31womenwithmoderate
depression.
aThe Odds Ratio was calculated for patients homozygous or heterozygous carrying risk allele vs.h o m o z y g o u s .
bFisher exact test was used for comparison of patients with depression versus patients without depression.
each genotype and compared with the homozygous values
for the genotype of higher frequency among controls, which
was set as the reference genotype. When the c.1460CC geno-
type was used as the reference, the combined c.1460CT +
TT genotypes were associated with higher risk of depression
(OR = 1.772; CI = 1.112–2.825, P = 0.0198).
17β-estradiol serum concentration was not associated
with depression in postmenopausal women. No signiﬁcant
diﬀerences in 17β-estradiol serum concentration were ob-
servedbetweenthehealthygroupofpostmenopausalwomen
without depression (r = 108.1pg/mL), the mild depression
(r = 102,1pg/mL),orthemoderatedepression(r = 74.2pg/
mL) patient subgroups.
Comparison of the 17β-estradiol serum concentration
between patients with diﬀerent genotypes of the MAO-A
c.1460C>T polymorphism yielded a signiﬁcant diﬀerence
between the patients with wild-type or heterozygous geno-
types(1460CCor1460CT,resp.)andthosewiththehomozy-
gous genotype variant (1460TT) (Kruskall-Wallis, χ2 =
11.960, P = 0.0025). In the subgroup of the homozygous
1460TT genotype, a signiﬁcantly higher 17β- estradiol con-
centration was observed (r = 130.03pg/mL) as comparedThe Scientiﬁc World Journal 5
to the 1460CT (r = 88.64pg/mL; P = 0.0065) or 1460CC
(r = 83.173pg/mL; P = 0.0018) genotypes.
No signiﬁcant correlations between plasma levels of 17β-
estradiolandtheotherSNPgenotypevariantswereobserved.
4. Discussion
We found a signiﬁcant contribution of the MAO-A
c.1460C>T polymorphic variant to depression in postmen-
opausal women. An association between the MAO-A CT and
TT genotypes and depression in postmenopausal women
has been evidenced. A C-to-T substitution at the third base
of codon470 in exon14 (Asp470Asp) of MAO-A results in
EcoRV restriction length polymorphism. To date, signiﬁcant
associations have been observed between the T allele for the
MAO-AEcoRVpolymorphismandhighMAOAactivity,with
levels ranging more than 50-fold among control subjects,
as measured in cultured skin ﬁbroblasts [28]. We provide
evidence for an association between depression in postmen-
opausal women and the T allele of the MAO-A gene, pre-
viously linked to high MAOA enzymatic activity [26–28].
These ﬁndings are in agreement with the well-established
action of MAOA inhibitors as antidepressants.
High-activity variants of the MAO-A gene have been also
associated with OCD. This association, however, has been
detectedamongOCDmaleswithcomorbidmajordepressive
disorder, more likely having the high-activity T allele of the
MAO-A gene than controls [23–25]. On the other hand,
femaleswithOCDweremorefrequentlyhomozygousforthe
low-activity C allele of the MAO-A EcoRV variant compared
to controls, with this allele also more frequent in female
patients than in controls [26]. Considering that the MAO-
A gene is localized to the X chromosome, our results may
supportasexuallydimorphic associationbetweenthegender
groups as reported by others and the occurrence of alleles
of the MAO-A gene polymorphism. These discrepancies,
however, might also be due to the diﬀerent populations that
have been studied.
Thefairlylowrelativeriskofdepressionobservedinpost-
menopausal women having the CT or TT genotypes (OR =
1.772) may be explained by a predisposition of patients in
the postmenopausal period to depression by a variant that
may not be in the MAO-A gene but within a closely linked,
yet-to-be-discovered susceptibility gene. The most likely
explanation, however, is that the linked, functional, MAO-
A high-activity variant has low penetrance or imposes a risk
on only a subset of postmenopausal women with depression.
This theory is consistent with previous reports of a beneﬁcial
eﬀectof MAOA inhibitors in certainOCD cases,although, in
general, treatment of OCD with MAOA inhibitors does not
seem to be as eﬀective as treatment with selective serotonin
reuptake inhibitors (SSRIs) [34]. An association between
high-activity variants of the MAO-A gene and depression
in postmenopausal women suggests, however, that some of
them will also respond well to MAO inhibitors.
Estrogen likely promotes serotoninergic neurotransmis-
sion by inﬂuencing release, metabolism, reuptake, or synthe-
sis[35].Ithasbeenreportedthatwomenwithahigh-activity
MAO-A genotype diﬀer from men and from women with
a low-activity genotype, which suggests that women with a
high-activity MAO-A genotype may drive some previously
reported sex diﬀerences in serotoninergic mechanisms [36].
Among women, but not among men, the concentration of
the major serotonin metabolite, 5-hydroxyindoleacetic acid
(Figure 1), was greater in those with a high-activity genotype
than in those with a low-activity genotype [36]. For healthy
women, plasma MAO activity is lowest at the time of ovula-
tion, when 17β-estradiol production is greatest, but MAO
activity increases during the luteal phase, when progesterone
is secreted [30]. The estrogen deﬁciency of postmenopausal
women who have not used HRT results in higher MAO
activity. This may have an inﬂuence on the risk of depressive
disorders in postmenopausal women [31–33]. Nevertheless,
the genetic association between the MAO-A EcoRV polymor-
phism and depression has never been analyzed in postmen-
opausal women. Several lines of evidence support the hy-
pothesis of an antidepressant eﬀect of estrogens exerted via
inhibition of the MAO pathway in women [37]. High-dose
estrogen signiﬁcantly decreased MAOA activity in the hypo-
thalamus and amygdala in adult female rats, with no signif-
icant changes in MAOB activity in these areas of the brain
[38].
In a human neuroblastoma cell line with transfected
cDNA of the estrogen receptor (SK-ER3), estrogen receptor
activation by a physiological concentration of 17β-estradiol
was correlated with a marked decrease in MAOA activity
[39]. We did not determine MAOA activity in the blood
samples studied, and although concentrations of 5-HT and
17β-estradiol were measured, plasma levels of either 5-HT
or 17β-estradiol did not diﬀer between particular groups of
postmenopausal women. However, the Kruskal-Wallis test
revealed that the high-activity T allele of the MAO-A EcoRV
polymorphism is markedly associated with a higher 17β-
estradiol concentration, thus favoring the hypothesis of the
presence of a functional link between estrogen and MAOA
activity in human cells of neural origin. In fact, a reverse
causality in the relationship between high 17β-estradiol
levels and depression disorders may have a protective role
in the homozygous 1460TT MAO-A EcoRV subgroup of the
studied postmenopausal women. On the other hand, the
concentration of 17β-estradiol may not be suﬃcient in pre-
venting depression in postmenopausal women that are not
taking HRT [40].
We concluded that the 1460T allele of MAO-A appeared
with a signiﬁcantly higher frequency in depressed female
patients than in the control group, and the patients with the
1460CT + TT genotypes showed an increased risk of depres-
sion, which indicates that the 1460T allele of MAO-A may be
a risk factor for depression in postmenopausal women.
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